Strategic objectives

• Development of new therapies for the prevention of bronchopulmonary dysplasia.
• Evaluation of new therapies for PAH.
• Evaluation of new drugs in pediatrics.
• Medium- and long-term prognosis and quality of life in congenital heart disease.
• Genetic mapping of type 1 diabetes mellitus.
• Development, implementation, and dissemination of new technologies for type 1 diabetes mellitus in children and adolescents.
• New insulins for type 1 diabetes mellitus in children and adolescents.
• Lifestyle habits, prevention, and treatment of childhood obesity.
• Epidemiology and genetic analysis of rare diseases: pseudohypoparathyroidism (Spanish PHP Group), monogenic diabetes.
• Epidemiological studies of efficacy and safety in children receiving growth hormone therapy.
• Hyperandrogenism and type 1 diabetes.

Research lines

• Pulmonary arterial hypertension.
• Cell therapy for bronchopulmonary dysplasia.
• Markers for predicting the risk of developing bronchopulmonary dysplasia.
• Safety of new drugs in the pediatric population.
• Congenital heart disease in adolescents and adults.
• New technologies for type 1 diabetes.
• New drugs for type 1 diabetes in children and adolescents.
• Epidemiology and safety of pediatric hospital-acquired infections.
• Hyperandrogenism and type 1 diabetes mellitus.
• Pituitary tumors in children and adolescents.
• New imaging techniques for congenital heart defects.
• New techniques in pulmonary valve implantation.